Ashwin Ananthakrishnan

List of Articles by Year
in descending order

Source: //exaly.com/author-pdf/6910490/publications.pdf

Version: 2025-02-01

415 peer-reviewed articles	29,554 peer-reviewed citations	10277 71 peer-reviewed h-index	460697 4.04 score
470 documents	32645 doc citations	11404 75 h-index	56131 citing authors

#	Article	IF	Citations
1	IBD Is Like a Tree: Reflections From Older Adults With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2025, 31, 1041-1050.	2.3	6
2	Diet and Microbiome-Directed Therapy 2.0 for IBD. Clinical Gastroenterology and Hepatology, 2025, 23, 406-418.	5.0	37
3	A Study of Patient Concerns in the Modern Therapeutic Era of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2025, 31, 1595-1604.	2.3	9
4	Predicting Outcomes in Hospitalized Patients With Acute Severe Ulcerative Colitis in a Prospective Multicenter Cohort. Inflammatory Bowel Diseases, 2025, 31, 1548-1555.	2.3	4
5	Outcomes of Long-term Tumor Necrosis Factor Alpha Inhibitor Therapy Beyond 10 Years in Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2025, 23, 674-676.e1.	5.0	2
6	A Simple Endoscopic Score for Crohn's Disease (SES-CD) ≥ 7 Predicts Disease Progression. Alimentary Pharmacology and Therapeutics, 2025, 61, 1011-1018.	2.7	3
7	Assessment and reporting of extraintestinal manifestations and fatigue in phase 3 inflammatory bowel disease clinical trials. Journal of Crohn's and Colitis, 2025, 19, .	0.9	3
8	Generalizability of Randomized Controlled Trials to Routine Clinical Care in Ulcerative Colitis. Inflammatory Bowel Diseases, 2025, 31, 2088-2096.	2.3	5
9	Accelerating Earlier Access to Anti-TNF-α Agents with Biosimilar Medicines in the Management of Inflammatory Bowel Disease. Journal of Clinical Medicine, 2025, 14, 1561.	1.8	7
10	Microbiota in inflammatory bowel disease: mechanisms of disease and therapeutic opportunities. Nature Reviews Microbiology, 2025, 23, 509-524.	58.2	212
11	A Comprehensive Review of Geriatric Syndromes and Assessment in Older Adults With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2025, 23, 1088-1101.	5.0	12
12	Epidemiology, Natural History, and Treatment of Inflammatory Bowel Disease in Africa: A Scoping Review. Clinical Gastroenterology and Hepatology, 2025, 24, 41-56.e11.	5.0	11
13	Existential Reflections by Older Adults With Inflammatory Bowel Diseases on Medical and Surgical Treatments. American Journal of Gastroenterology, 2025, 120, 1829-1838.	0.7	1
14	Liver Transplantation Is Associated With a Reduced Risk of Colorectal Dysplasia in Patients With IBD and Concomitant PSC. Clinical Gastroenterology and Hepatology, 2025, 24, 181-189.e2.	5.0	5
15	ACG Clinical Guideline Update: Ulcerative Colitis in Adults. American Journal of Gastroenterology, 2025, 120, 1187-1224.	0.7	173
16	Outcomes Associated With Anti-Depressant Use in Patients With Inflammatory Bowel Disease. Alimentary Pharmacology and Therapeutics, 2025, 62, 536-542.	2.7	3
17	An International Multicenter Study of Native and Immigrant South Asian Crohn's Disease. Clinical Gastroenterology and Hepatology, 2025, 24, 1121-1129.e6.	5.0	6
18	Geographic Inequities in Access to Phase 3 Clinical Trials for Inflammatory Bowel Disease in the United States. Clinical Gastroenterology and Hepatology, 2024, 22, 659-661.e3.	5.0	7

#	Article	IF	Citations
19	Risk of Cancer Recurrence in Patients With Immune-Mediated Diseases With Use of Immunosuppressive Therapies: An Updated Systematic Review and Meta-Analysis. Clinical Gastroenterology and Hepatology, 2024, 22, 499-512.e6.	5.0	35
20	Differences in Management and Outcomes of Older and Younger Adults with Acute Severe Ulcerative Colitis. Journal of Crohn's and Colitis, 2024, 18, 570-577.	0.9	11
21	Precision medicine in inflammatory bowel diseases. Intestinal Research, 2024, 22, 8-14.	2.3	19
22	Differential Impact of Smoking on Methylome and Transcriptome in Crohn's Disease and Ulcerative Colitis. Inflammatory Bowel Diseases, 2024, 30, 981-991.	2.3	12
23	Pharmacoequity for Older Adults With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2024, 22, 209-214.	5.0	1
24	Pharmacoequity for Older Adults With Inflammatory Bowel Diseases. Gastroenterology, 2024, 166, 235-239.	0.9	3
25	Prevalence and Appropriateness of Polypharmacy in Older Adults with Inflammatory Bowel Diseases. Digestive Diseases and Sciences, 2024, 69, 766-774.	1.5	14
26	Risk of Common Neurological Disorders in Adult Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflammatory Bowel Diseases, 2024, 30, 2195-2204.	2.3	24
27	Meta-analysis: Risk of pancreatic cancer in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2024, 59, 918-927.	2.7	16
28	Physical Activity is Associated with a Decreased Risk of Developing Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Journal of Crohn's and Colitis, 2024, 18, 1476-1485.	0.9	24
29	Discovery of disease-adapted bacterial lineages in inflammatory bowel diseases. Cell Host and Microbe, 2024, 32, 1147-1162.e12.	12.2	52
30	Risk Factors for the Development of and Outcomes After Diagnosis of Autoimmune Alopecia Areata in Patients with Inflammatory Bowel Diseases. Digestive Diseases and Sciences, 2024, 69, 3375-3381.	1.5	6
31	Meta-analysis: Risk of lymphoma in patients with inflammatory bowel disease in population-based cohort studies. Alimentary Pharmacology and Therapeutics, 2024, 60, 1264-1275.	2.7	10
32	Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis. Gastroenterology, 2024, 167, 1460-1482.	0.9	81
33	S1146 Inflammatory Bowel Disease (IBD)-Associated Peripheral Arthritis is Not Associated With Objective Markers of Luminal IBD Disease Activity - Results From the CHASE Cohort. American Journal of Gastroenterology, 2024, 119, S814-S815.	0.7	0
34	AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis. Gastroenterology, 2024, 167, 1307-1343.	0.9	195
35	Fecal Calprotectin as a Biomarker for Disease Activity in Microscopic Colitis. Journal of Clinical Gastroenterology, 2024, 59, 996-999.	1.6	0
36	Prevalence and Prognosis of Mild Inflammatory Bowel Disease: A Population-based Cohort Study, 1997–2020. Clinical Gastroenterology and Hepatology, 2024, 23, 2570-2578.e7.	5.0	10

#	Article	IF	Citations
37	Differential Efficacy of Advanced Therapies in Inducing Remission in Ulcerative Colitis Based on Prior Exposure to TNF Antagonists. Clinical Gastroenterology and Hepatology, 2024, 23, 2102-2114.e5.	5.0	16
38	Inflammatory Bowel Disease Is Associated With Prediagnostic Perturbances in Metabolic Pathways. Gastroenterology, 2023, 164, 147-150.e2.	0.9	38
39	Histologic Activity in an Endoscopically Normal-Appearing Pouch Predicts Future Risk of Pouchitis in Patients With Ulcerative Colitis. American Journal of Gastroenterology, 2023, 118, 174-177.	0.7	8
40	Lifestyle factors for the prevention of inflammatory bowel disease. Gut, 2023, 72, 1093-1100.	10.3	76
41	Food Processing and Risk of Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis. Clinical Gastroenterology and Hepatology, 2023, 21, 2483-2495.e1.	5.0	100
42	Remodeling of colon plasma cell repertoire within ulcerative colitis patients. Journal of Experimental Medicine, 2023, 220, .	5.9	40
43	Mild Crohn's Disease: Definition and Management. Current Gastroenterology Reports, 2023, 25, 45-51.	2.2	25
44	AGA Clinical Practice Guideline on the Role of Biomarkers for the Management of Ulcerative Colitis. Gastroenterology, 2023, 164, 344-372.	0.9	156
45	Comparative Effectiveness of Upadacitinib and Tofacitinib in Inducing Remission in Ulcerative Colitis: Real-World Data. Clinical Gastroenterology and Hepatology, 2023, 21, 2427-2429.e1.	5.0	46
46	Genetic coding variant in complement factor B (CFB) is associated with increased risk for perianal Crohn's disease and leads to impaired CFB cleavage and phagocytosis. Gut, 2023, 72, 2068-2080.	10.3	22
47	Economic Burden of Fatigue in Inflammatory Bowel Disease. Crohn's & Colitis 360, 2023, 5, .	1.1	15
48	Content Validity and Psychometric Evaluation of the Functional Assessment of Chronic Illness Therapy–Fatigue (FACIT–Fatigue) in Patients with Crohn's Disease and Ulcerative Colitis. PharmacoEconomics - Open, 2023, 7, 823-840.	1.3	16
49	Longitudinal trajectories of anxiety, depression, and bipolar disorder in inflammatory bowel disease: a population-based cohort study. EClinicalMedicine, 2023, 59, 101986.	6.6	45
50	A Narrative Review of Financial Burden, Distress, and Toxicity of Inflammatory Bowel Diseases in the United States. American Journal of Gastroenterology, 2023, 118, 1545-1553.	0.7	37
51	Periodontal disease is not associated with risk of inflammatory bowel disease: Results from two prospective cohort studies in the US. Alimentary Pharmacology and Therapeutics, 2023, 58, 1052-1061.	2.7	13
52	S877 Diagnosis of Inflammatory Bowel Disease Associated Peripheral Arthritis: A Systematic Review. American Journal of Gastroenterology, 2023, 118, S653-S653.	0.7	0
53	S937 Dietary Nut and Legume Intake and Risk of Inflammatory Bowel Disease in US Adults. American Journal of Gastroenterology, 2023, 118, S702-S702.	0.7	1
54	AGA Clinical Practice Guideline on the Role of Biomarkers for the Management of Crohn's Disease. Gastroenterology, 2023, 165, 1367-1399.	0.9	108

#	Article	IF	Citations
55	Vedolizumab or Tumor Necrosis Factor Antagonist Use and Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease With Prior Malignancy: A Retrospective Cohort Study. Clinical Gastroenterology and Hepatology, 2022, 20, 88-95.	5.0	48
56	Dietary Gluten Intake Is Not Associated With Risk of Inflammatory Bowel Disease in US Adults Without Celiac Disease. Clinical Gastroenterology and Hepatology, 2022, 20, 303-313.e6.	5.0	16
57	Yield and Predictors of Surveillance Colonoscopies in Older Adults With Long-standing Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2022, 20, e1353-e1364.	5.0	7
58	Ultra-processed Foods and Risk of Crohn's Disease and Ulcerative Colitis: A Prospective Cohort Study. Clinical Gastroenterology and Hepatology, 2022, 20, e1323-e1337.	5.0	157
59	Vedolizumab Is Associated With a Lower Risk of Serious Infections Than Anti-Tumor Necrosis Factor Agents in Older Adults. Clinical Gastroenterology and Hepatology, 2022, 20, 1299-1305.e5.	5.0	43
60	Alcohol Consumption is Associated With An Increased Risk of Microscopic Colitis: Results From 2 Prospective US Cohort Studies. Inflammatory Bowel Diseases, 2022, 28, 1151-1159.	2.3	12
61	Plasma concentrations of perfluoroalkyl substances and risk of inflammatory bowel diseases in women: A nested case control analysis in the Nurses' Health Study cohorts. Environmental Research, 2022, 207, 112222.	5.7	25
62	Risk of Infections With Ustekinumab and Tofacitinib Compared to Tumor Necrosis Factor α Antagonists in Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2022, 20, 2366-2372.e6.	5.0	41
63	Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases. The Lancet Gastroenterology and Hepatology, 2022, 7, 254-261.	15.0	35
64	Risk Factors for Incident Inflammatory Bowel Disease According to Disease Phenotype. Clinical Gastroenterology and Hepatology, 2022, 20, 2347-2357.e14.	5.0	17
65	Smoking Behaviour Changes After Diagnosis of Inflammatory Bowel Disease and Risk of All-cause Mortality. Journal of Crohn's and Colitis, 2022, 16, 1030-1038.	0.9	4
66	Fecal Calprotectin Is a Predictor of Need for Rescue Therapy in Hospitalized Severe Colitis. Inflammatory Bowel Diseases, 2022, 28, 1833-1837.	2.3	15
67	Comparative Risk of Thrombotic and Cardiovascular Events with Tofacitinib and Anti-TNF Agents in Patients with Inflammatory Bowel Diseases. Digestive Diseases and Sciences, 2022, 67, 5206-5212.	1.5	40
68	A United States expert consensus to standardise definitions, follow-up, and treatment targets for extra-intestinal manifestations in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2022, 55, 1179-1191.	2.7	30
69	Alcohol consumption and risk of inflammatory bowel disease among three prospective US cohorts. Alimentary Pharmacology and Therapeutics, 2022, 55, 225-233.	2.7	19
70	Sugars and Gastrointestinal Health. Clinical Gastroenterology and Hepatology, 2022, 20, 1912-1924.e7.	5.0	72
71	Recommendations on the Appropriate Management of Steroids and Discharge Planning During and After Hospital Admission for Moderate-Severe Ulcerative Colitis: Results of a RAND Appropriateness Panel. American Journal of Gastroenterology, 2022, 117, 1288-1295.	0.7	9
72	Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus. The Lancet Gastroenterology and Hepatology, 2022, 7, 666-678.	15.0	143

#	Article	IF	Citations
73	E-cigarette Use and Disease Outcomes in Inflammatory Bowel Diseases: A Case-Control Study. Digestive Diseases and Sciences, 2022, 68, 208-213.	1.5	10
74	Depression and anxiety in inflammatory bowel disease: epidemiology, mechanisms and treatment. Nature Reviews Gastroenterology and Hepatology, 2022, 19, 717-726.	33.1	541
75	Precision medicine: how multiomics will shape the future of inflammatory bowel disease?. Current Opinion in Gastroenterology, 2022, 38, 382-387.	1.6	17
76	Comorbidity Influences the Comparative Safety of Biologic Therapy in Older Adults With Inflammatory Bowel Diseases. American Journal of Gastroenterology, 2022, 117, 1845-1850.	0.7	28
77	Endogenous Levels of Circulating Androgens Are Not Associated with Risk of Microscopic Colitis. Digestive Diseases and Sciences, 2022, 68, 571-579.	1.5	2
78	Comparative Safety of Ustekinumab and Vedolizumab in Older Patients with Inflammatory Bowel Disease: A Bicentric Cohort Study. Journal of Clinical Medicine, 2022, 11, 6967.	1.8	9
79	Treat to Target: The Role of Histologic Healing in Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2021, 19, 1800-1813.e4.	5.0	147
80	Combination Therapy Does Not Improve Rate of Clinical or Endoscopic Remission in Patients with Inflammatory Bowel Diseases Treated With Vedolizumab or Ustekinumab. Clinical Gastroenterology and Hepatology, 2021, 19, 1366-1376.e2.	5.0	77
81	Frequency of Opioid Prescription at Emergency Department Discharge in Patients with Inflammatory Bowel Disease: A Nationwide Analysis. Clinical Gastroenterology and Hepatology, 2021, 19, 2064-2071.e1.	5.0	19
82	Robust and efficient semi-supervised estimation of average treatment effects with application to electronic health records data. Biometrics, 2021, 77, 413-423.	1.1	22
83	Healthy Lifestyle Is Associated With Reduced Mortality in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2021, 19, 87-95.e4.	5.0	79
84	Alterations in Fecal Microbiomes and Serum Metabolomes of Fatigued Patients With Quiescent Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2021, 19, 519-527.e5.	5.0	63
85	Phenotype and Natural History of Inflammatory Bowel Disease in Patients With Concomitant Eosinophilic Esophagitis. Inflammatory Bowel Diseases, 2021, 27, 469-475.	2.3	15
86	Characteristics and Long-Term Outcomes of Pregnancy-Onset Inflammatory Bowel Disease: A Case-Control Study. Inflammatory Bowel Diseases, 2021, 27, 476-481.	2.3	9
87	Ileal or Colonic Histologic Activity Is Not Associated With Clinical Relapse in Patients With Crohn's Disease in Endoscopic Remission. Clinical Gastroenterology and Hepatology, 2021, 19, 1226-1233.e1.	5.0	25
88	Safety and Efficacy of Tumor Necrosis Factor Antagonists in Older Patients With Ulcerative Colitis: Patient-Level Pooled Analysis of Data From Randomized Trials. Clinical Gastroenterology and Hepatology, 2021, 19, 939-946.e4.	5.0	46
89	AGA Clinical Practice Update on Management of Inflammatory Bowel Disease in Elderly Patients: Expert Review. Gastroenterology, 2021, 160, 445-451.	0.9	86
90	Immunosuppressive Therapy and Risk of COVID-19 Infection in Patients With Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2021, 27, 155-161.	2.3	59

#	Article	IF	Citations
91	Yield of Random Biopsies During Colonoscopies in Inflammatory Bowel Disease Patients Undergoing Dysplasia Surveillance. Inflammatory Bowel Diseases, 2021, 27, 779-786.	2.3	37
92	Diet in Treatment of Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2021, 19, 425-435.e3.	5.0	117
93	Frailty in inflammatory bowel diseases: an emerging concept. Therapeutic Advances in Gastroenterology, 2021, 14, .	2.0	44
94	Economic burden and cost-effectiveness of therapies for Clostridiodes difficile infection: a narrative review. Therapeutic Advances in Gastroenterology, 2021, 14, .	2.0	60
95	Increasing Prevalence of Frailty and Its Association with Readmission and Mortality Among Hospitalized Patients with IBD. Digestive Diseases and Sciences, 2021, 66, 4178-4190.	1.5	72
96	Time to Negative SARS-CoV-2 PCR Should Not Delay Care Among Patients With Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2021, 27, 590-592.	2.3	0
97	Nutrition in the Management of Inflammatory Bowel Diseases. Gastroenterology Clinics of North America, 2021, 50, 151-167.	1.6	8
98	Systematic Review of Inclusion and Analysis of Older Adults in Randomized Controlled Trials of Medications Used to Treat Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2021, 27, 1541-1543.	2.3	45
99	Inflammatory Bowel Disease Patients Who Respond to Treatment with Anti-tumor Necrosis Factor Agents Demonstrate Improvement in Pre-treatment Frailty. Digestive Diseases and Sciences, 2021, 67, 622-628.	1.5	44
100	Therapeutic Drug Monitoring of Non-Anti-Tumor Necrosis Factor Biologics. Clinical Gastroenterology and Hepatology, 2021, 19, 1108-1110.	5.0	9
101	High Anti-Infliximab Antibody Titers Do Not Impact Response to Subsequent Adalimumab Treatment in Inflammatory Bowel Diseases. Digestive Diseases and Sciences, 2021, 67, 3124-3128.	1.5	5
102	Plant-Based Diet Quality and Risk of Crohn's Disease and Ulcerative Colitis in US Women. Current Developments in Nutrition, 2021, 5, 462.	0.3	2
103	Multi-omics reveal microbial determinants impacting responses to biologic therapies in inflammatory bowel disease. Cell Host and Microbe, 2021, 29, 1294-1304.e4.	12.2	228
104	Efficacy and Safety of Fecal Transplantation Versus Targeted Therapies in Ulcerative Colitis: Network Meta-Analysis. Future Microbiology, 2021, 16, 1215-1227.	1.4	18
105	Immune-mediated diseases and risk of Crohn's disease or ulcerative colitis: a prospective cohort study. Alimentary Pharmacology and Therapeutics, 2021, 53, 598-607.	2.7	26
106	Longitudinal Trajectory of Fatigue in Patients With Inflammatory Bowel Disease: A Prospective Study. Inflammatory Bowel Diseases, 2021, 27, 1740-1746.	2.3	31
107	Women's Willingness to Accept Risks of Medication for Inflammatory Bowel Disease During Pregnancy. Patient, 2021, 15, 353-365.	1.8	5
108	Discordance Between Patient-Reported Outcomes and Mucosal Inflammation in Patients With Mild to Moderate Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2020, 18, 1760-1768.e1.	5.0	48

#	Article	IF	Citations
109	Ulcerative Colitis and Crohn's Disease Have Similar Burden and Goals for Treatment. Clinical Gastroenterology and Hepatology, 2020, 18, 14-23.	5.0	231
110	Association Between Vulvovaginal Discomfort and Activity of Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2020, 18, 604-611.e1.	5.0	23
111	Opportunistic Infections Are More Prevalent in Crohn's Disease and Ulcerative Colitis: A Large Population-Based Study. Inflammatory Bowel Diseases, 2020, 26, 291-300.	2.3	32
112	Longitudinal Trajectory of Fatigue With Initiation of Biologic Therapy in Inflammatory Bowel Diseases: A Prospective Cohort Study. Journal of Crohn's and Colitis, 2020, 14, 309-315.	0.9	54
113	Acute Venous Thromboembolism Risk Highest Within 60 Days After Discharge From the Hospital in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2020, 18, 1133-1141.e3.	5.0	65
114	Complete histologic normalisation is associated with reduced risk of relapse among patients with ulcerative colitis in complete endoscopic remission. Alimentary Pharmacology and Therapeutics, 2020, 51, 347-355.	2.7	71
115	Use of Narrative Concepts in Electronic Health Records to Validate Associations Between Genetic Factors and Response to Treatment of Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2020, 18, 1890-1892.	5.0	2
116	Estimating average treatment effects with a double-index propensity score. Biometrics, 2020, 76, 767-777.	1.1	15
117	Incidence and Predictors of Flares in the Postpartum Year Among Women With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2020, 26, 1926-1932.	2.3	47
118	Hormone Therapy for Cancer Is a Risk Factor for Relapse of Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2020, 18, 872-880.e1.	5.0	25
119	Infliximab Trough Levels Are Not Predictive of Relapse in Patients with IBD in Endoscopic Remission: A Multicenter Cohort Study. Digestive Diseases and Sciences, 2020, 66, 3548-3554.	1.5	8
120	Assessment of Benefit of Advanced Inflammatory Bowel Disease Training: Challenges and Solutions. Crohn's & Colitis 360, 2020, 2, .	1.1	5
121	Disease and Treatment Patterns Among Patients With Pouch-related Conditions in a Cohort of Large Tertiary Care Inflammatory Bowel Disease Centers in the United States. Crohn's & Colitis 360, 2020, 2, .	1.1	10
122	Multi-"-Omics" Profiling in Patients With Quiescent Inflammatory Bowel Disease Identifies Biomarkers Predicting Relapse. Inflammatory Bowel Diseases, 2020, 26, 1524-1532.	2.3	52
123	Changing Global Epidemiology of Inflammatory Bowel Diseases: Sustaining Health Care Delivery Into the 21st Century. Clinical Gastroenterology and Hepatology, 2020, 18, 1252-1260.	5.0	263
124	Dietary Inflammatory Potential and Risk of Crohn's Disease and Ulcerative Colitis. Gastroenterology, 2020, 159, 873-883.e1.	0.9	161
125	Sa1836 FRAILTY AS A RISK FACTOR FOR HOSPITAL READMISSION IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE: A NATIONWIDE STUDY. Gastroenterology, 2020, 158, S-445-S-446.	0.9	1
126	Case 8-2020: An 89-Year-Old Man with Recurrent Abdominal Pain and Bloody Stools. New England Journal of Medicine, 2020, 382, 1042-1052.	26.4	1

#	Article	IF	Citations
127	Risk of Tuberculosis in Patients With Inflammatory Bowel Disease on Infliximab or Adalimumab Is Dependent on the Local Disease Burden of Tuberculosis: A Systematic Review and Meta-Analysis. American Journal of Gastroenterology, 2020, 115, 340-349.	0.7	68
128	Frailty is independently associated with mortality in 11 001 patients with inflammatory bowel diseases. Alimentary Pharmacology and Therapeutics, 2020, 52, 311-318.	2.7	76
129	Assessment of Body Weight Changes in Patients with Inflammatory Bowel Diseases Initiating Biologic Therapy: A Prospective Cohort Study. Digestive Diseases and Sciences, 2020, 65, 3672-3678.	1.5	12
130	Pretreatment Frailty Is Independently Associated With Increased Risk of Infections After Immunosuppression in Patients With Inflammatory Bowel Diseases. Gastroenterology, 2020, 158, 2104-2111.e2.	0.9	125
131	Management of Inflammatory Bowel Diseases: Clinical Perspectives. Clinical Gastroenterology and Hepatology, 2020, 18, 1249-1251.	5.0	1
132	Dietary Guidance From the International Organization for the Study of Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2020, 18, 1381-1392.	5.0	281
133	Assessing National Trends and Disparities in Ambulatory, Emergency Department, and Inpatient Visits for Inflammatory Bowel Disease in the United States (2005–2016). Clinical Gastroenterology and Hepatology, 2020, 18, 2500-2509.e1.	5.0	36
134	Automated ICD coding via unsupervised knowledge integration (UNITE). International Journal of Medical Informatics, 2020, 139, 104135.	2.6	30
135	Microbiome-Based Biomarkers for IBD. Inflammatory Bowel Diseases, 2020, 26, 1463-1469.	2.3	40
136	A Phenome-Wide Analysis of Healthcare Costs Associated with Inflammatory Bowel Diseases. Digestive Diseases and Sciences, 2020, 66, 760-767.	1.5	15
137	Impact of Diet on Risk of IBD. Crohn's & Colitis 360, 2020, 2, .	1.1	11
138	Reply. Clinical Gastroenterology and Hepatology, 2019, 17, 1919.	5.0	0
139	Intra- and Inter-cellular Rewiring of the Human Colon during Ulcerative Colitis. Cell, 2019, 178, 714-730.e22.	23.4	1,430
140	The Role of the Radiologist in Determining Disease Severity in Inflammatory Bowel Diseases. Gastrointestinal Endoscopy Clinics of North America, 2019, 29, 447-470.	1.1	58
141	Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data. Advances in Therapy, 2019, 36, 3079-3095.	2.7	28
142	P063 SAFETY OF BIOLOGIC THERAPY IN OLDER PATIENTS WITH IMMUNE-MEDIATED DISEASES: A SYSTEMATIC REVIEW AND META-ANALYSIS. Inflammatory Bowel Diseases, 2019, 25, S30-S30.	2.3	1
143	Immunologic Alterations Associated With Oral Delivery of Anti-CD3 (OKT3) Monoclonal Antibodies in Patients With Moderate-to-Severe Ulcerative Colitis. Crohn's & Colitis 360, 2019, 1, .	1.1	18
144	Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature, 2019, 569, 655-662.	30.7	3,040

#	Article	IF	Citations
145	Low-dose Methotrexate has Similar Outcomes to High-dose Methotrexate in Combination with Anti-TNF Therapy in Inflammatory Bowel Diseases. Journal of Crohn's and Colitis, 2019, 13, 990-995.	0.9	10
146	Safety of Biologic Therapy in Older Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology, 2019, 17, 1736-1743.e4.	5.0	130
147	Obesity and Weight Gain Since Early Adulthood Are Associated With a Lower Risk of Microscopic Colitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2523-2532.e1.	5.0	27
148	Association of Genetic Variants in NUDT15 With Thiopurine-Induced Myelosuppression in Patients With Inflammatory Bowel Disease. JAMA - Journal of the American Medical Association, 2019, 321, 773.	14.4	176
149	CT-Visualized Colonic Mural Stratification Independently Predicts the Need for Medical or Surgical Rescue Therapy in Hospitalized Ulcerative Colitis Patients. Digestive Diseases and Sciences, 2019, 64, 2265-2272.	1.5	5
150	Comparative safety and effectiveness of tumor necrosis factor α antagonists and vedolizumab in elderly IBD patients: a multicentre study. Alimentary Pharmacology and Therapeutics, 2019, 49, 873-879.	2.7	96
151	ACG Clinical Guideline: Ulcerative Colitis in Adults. American Journal of Gastroenterology, 2019, 114, 384-413.	0.7	1,494
152	Second-Look Endoscopy in Hospitalized Severe Ulcerative Colitis: A Retrospective Cohort Study. Inflammatory Bowel Diseases, 2019, 25, 750-755.	2.3	13
153	Effect of Accelerated Infliximab Induction on Short- and Long-term Outcomes of Acute Severe Ulcerative Colitis: A Retrospective Multicenter Study and Meta-analysis. Clinical Gastroenterology and Hepatology, 2019, 17, 502-509.e1.	5.0	98
154	Comparable perioperative outcomes, long-term outcomes, and quality of life in a retrospective analysis of ulcerative colitis patients following 2-stage versus 3-stage proctocolectomy with ileal pouch-anal anastomosis. International Journal of Colorectal Disease, 2019, 34, 491-499.	1.5	49
155	Cancer risk in microscopic colitis: a retrospective cohort study. BMC Gastroenterology, 2019, 19, .	1.7	52
156	The Gut Microbiome and Digestive Health – A New Frontier. Clinical Gastroenterology and Hepatology, 2019, 17, 215-217.	5.0	9
157	Paternal Disease Activity Is Associated With Difficulty in Conception Among Men With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2019, 17, 203-204.	5.0	12
158	Interval Colorectal Cancer in Inflammatory Bowel Disease: The Role of Guideline Adherence. Digestive Diseases and Sciences, 2019, 65, 111-118.	1.5	23
159	Smoking is Associated with an Increased Risk of Microscopic Colitis: Results From Two Large Prospective Cohort Studies of US Women. Journal of Crohn's and Colitis, 2018, 12, 559-567.	0.9	36
160	Loss of Response to Anti-Tumor Necrosis Factor Alpha Therapy in Crohn's Disease Is Not Associated with Emergence of Novel Inflammatory Pathways. Digestive Diseases and Sciences, 2018, 63, 738-745.	1.5	21
161	Enabling phenotypic big data with PheNorm. Journal of the American Medical Informatics Association: JAMIA, 2018, 25, 54-60.	3.3	115
162	Dynamics of metatranscription in the inflammatory bowel disease gut microbiome. Nature Microbiology, 2018, 3, 337-346.	9.9	580

#	Article	IF	Citations
163	Differences in Clinical Course, Genetics, and the Microbiome Between Familial and Sporadic Inflammatory Bowel Diseases. Journal of Crohn's and Colitis, 2018, 12, 525-531.	0.9	31
164	Genetic Markers Predict Primary Nonresponse and Durable Response to Anti–Tumor Necrosis Factor Therapy in Ulcerative Colitis. Inflammatory Bowel Diseases, 2018, 24, 1840-1848.	2.3	49
165	Depression but Not Symptom Severity is Associated With Work and School Absenteeism in Refractory Chronic Constipation. Journal of Clinical Gastroenterology, 2018, 52, 407-412.	1.6	12
166	Effect of oral tobacco use and smoking on outcomes of Crohn's disease in India. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 134-140.	1.8	19
167	Ethnicity Influences Phenotype and Outcomes in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis of Population-based Studies. Clinical Gastroenterology and Hepatology, 2018, 16, 190-197.e11.	5.0	121
168	Use of Biologic Therapy by Pregnant Women With Inflammatory Bowel Disease Does Not Affect Infant Response to Vaccines. Clinical Gastroenterology and Hepatology, 2018, 16, 99-105.	5.0	124
169	"Weekend Effect" in Patients With Upper Gastrointestinal Hemorrhage: A Systematic Review and Meta-analysis. American Journal of Gastroenterology, 2018, 113, 13-21.	0.7	44
170	Identification of Menopausal and Reproductive Risk Factors for Microscopic Colitis—Results From the Nurses' Health Study. Gastroenterology, 2018, 155, 1764-1775.e2.	0.9	38
171	Bugs and drugs: Predicting response to therapy. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 27-27.	1.8	0
172	The Effect of Early-Life Environmental Exposures on Disease Phenotype and Clinical Course of Crohn's Disease in Children. American Journal of Gastroenterology, 2018, 113, 1524-1529.	0.7	44
173	Making sense of clinical predictors. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 7-8.	1.8	0
174	Debate session: So what causes inflammatory bowel disease? It's all in the environment. Journal of Gastroenterology and Hepatology (Australia), 2018, 33, 24-24.	1.8	6
175	The role of diet in the aetiopathogenesis of inflammatory bowel disease. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 525-535.	33.1	266
176	Lack of Difference in Treatment Patterns and Clinical Outcomes Between Black and White Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 2634-2640.	2.3	26
177	IRGMGene Variants Modify the Relationship Between Visceral Adipose Tissue and NAFLD in Patients With Crohn's Disease. Inflammatory Bowel Diseases, 2018, 24, 2247-2257.	2.3	22
178	Does Obesity Influence the Risk of Clostridium difficile Infection Among Patients with Ulcerative Colitis?. Digestive Diseases and Sciences, 2018, 63, 2445-2450.	1.5	13
179	The Association Between Arthralgia and Vedolizumab Using Natural Language Processing. Inflammatory Bowel Diseases, 2018, 24, 2242-2246.	2.3	32
180	Reply. Clinical Gastroenterology and Hepatology, 2018, 16, 1177.	5.0	0

#	Article	IF	Citations
181	Development of a Sexual Dysfunction Scale for Women With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2018, 24, 2350-2359.	2.3	40
182	Long-Term Outcomes of Immunosuppression-Naïve Steroid Responders Following Hospitalization for Ulcerative Colitis. Digestive Diseases and Sciences, 2018, 63, 2740-2746.	1.5	11
183	Reply to 'Comment on Sarcopenia is a Novel Predictor of the Need for Rescue Therapy in Hospitalized Ulcerative Colitis Patients'. Journal of Crohn's and Colitis, 2018, 12, 1256-1256.	0.9	35
184	Sarcopenia is a Novel Predictor of the Need for Rescue Therapy in Hospitalized Ulcerative Colitis Patients. Journal of Crohn's and Colitis, 2018, , .	0.9	36
185	Predictability and persistence of prebiotic dietary supplementation in a healthy human cohort. Scientific Reports, 2018, 8, .	2.7	44
186	A low-cost paper-based synthetic biology platform for analyzing gut microbiota and host biomarkers. Nature Communications, 2018, 9, .	10.8	241
187	Fatigue in IBD: epidemiology, pathophysiology and management. Nature Reviews Gastroenterology and Hepatology, 2018, 16, 247-259.	33.1	241
188	Non-Steroidal Anti-Inflammatory Drugs and Aspirin, but Not Acetaminophen, Are Associated With an Increased Risk of Microscopic Colitis: Results From the Nurses' Health Studies. American Journal of Gastroenterology, 2018, 113, S59-S60.	0.7	1
189	Nutritional Adequacy of Popular Defined Diets for Inflammatory Bowel Disease. American Journal of Gastroenterology, 2018, 113, S415.	0.7	0
190	The impact of co-existing immune-mediated diseases on phenotype and outcomes in inflammatory bowel diseases. Alimentary Pharmacology and Therapeutics, 2017, 45, 814-823.	2.7	41
191	Risk of colorectal cancer in Asian patients with ulcerative colitis: a systematic review and meta-analysis. The Lancet Gastroenterology and Hepatology, 2017, 2, 269-276.	15.0	204
192	Genetic risk factors for serious infections in inflammatory bowel diseases. Scandinavian Journal of Gastroenterology, 2017, 52, 570-576.	1.1	8
193	Modifiable Environmental Factors in Inflammatory Bowel Disease. Current Gastroenterology Reports, 2017, 19, .	2.2	31
194	Management of Inflammatory Bowel Disease in the Elderly Patient. Inflammatory Bowel Diseases, 2017, 23, 882-893.	2.3	105
195	Inflammatory Bowel Disease is Similar in Patients with Older Onset and Younger Onset. Inflammatory Bowel Diseases, 2017, 23, 1187-1194.	2.3	22
196	Gut Microbiome Function Predicts Response to Anti-integrin Biologic Therapy in Inflammatory Bowel Diseases. Cell Host and Microbe, 2017, 21, 603-610.e3.	12.2	449
197	The benefit of combination therapy depends on disease phenotype and duration in Crohn's disease. Alimentary Pharmacology and Therapeutics, 2017, 46, 162-168.	2.7	17
198	Clostridium difficile Infection and Risk of Colectomy in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2017, 23, 200-207.	2.3	35

#	Article	IF	Citations
199	Older Age- and Health-related Quality of Life in Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2017, 23, 283-288.	2.3	24
200	Distance to Specialist Care and Disease Outcomes in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2017, 23, 1234-1239.	2.3	42
201	Dietary Iron and Heme Iron Consumption, Genetic Susceptibility, and Risk of Crohn's Disease and Ulcerative Colitis. Inflammatory Bowel Diseases, 2017, 23, 1088-1095.	2.3	49
202	Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn's disease and ulcerative colitis controlled trials. Alimentary Pharmacology and Therapeutics, 2017, 45, 1291-1302.	2.7	282
203	Predictors of Clinical Response and Remission at 1 Year Among a Multicenter Cohort of Patients with Inflammatory Bowel Disease Treated with Vedolizumab. Digestive Diseases and Sciences, 2017, 62, 1590-1596.	1.5	68
204	Genetic Polymorphisms in Fatty Acid Metabolism Modify the Association Between Dietary n3. Inflammatory Bowel Diseases, 2017, 23, 1898-1904.	2.3	38
205	Systematic review with meta-analysis: breastfeeding and the risk of Crohn's disease and ulcerative colitis. Alimentary Pharmacology and Therapeutics, 2017, 46, 780-789.	2.7	240
206	Genetic Polymorphisms in Fatty Acid Metabolism Modify the Association Between Dietary N3:N6 Intake and Risk of Ulcerative Colitis. Gastroenterology, 2017, 152, S60.	0.9	1
207	Issue Highlights. Clinical Gastroenterology and Hepatology, 2017, 15, 961-965.	5.0	0
208	Surrogate-assisted feature extraction for high-throughput phenotyping. Journal of the American Medical Informatics Association: JAMIA, 2017, 24, e143-e149.	3.3	80
209	Pivot to Asia: inflammatory bowel disease burden. Intestinal Research, 2017, 15, 138.	2.3	96
210	The emergence of Clostridium difficile infection in Asia: A systematic review and meta-analysis of incidence and impact. PLoS ONE, 2017, 12, e0176797.	1.5	109
211	Environmental triggers in IBD: a review of progress and evidence. Nature Reviews Gastroenterology and Hepatology, 2017, 15, 39-49.	33.1	902
212	A Case Study of the Incremental Utility for Disease Identification of Natural Language Processing in Electronic Medical Records. Pharmaceutical Medicine, 2017, 32, 31-37.	2.4	8
213	Does Obesity Influence the Risk of C. difficile Infection Among Patients with Ulcerative Colitis?. American Journal of Gastroenterology, 2016, 111, S302.	0.7	0
214	Identification and Characterization of a Novel Association between Dietary Potassium and Risk of Crohn's Disease and Ulcerative Colitis. Frontiers in Immunology, 2016, 7, .	3.3	50
215	Rising Educators, Academicians, and Clinicians Helping Inflammatory Bowel Disease (REACH-IBD)—Promoting Improvement of Inflammatory Bowel Disease Education in the United States. Inflammatory Bowel Diseases, 2016, 22, 1531-1532.	2.3	3
216	Identification of Nonresponse to Treatment Using Narrative Data in an Electronic Health Record Inflammatory Bowel Disease Cohort. Inflammatory Bowel Diseases, 2016, 22, 151-158.	2.3	19

#	Article	IF	Citations
217	Environmental Hygiene and Risk of Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2016, 22, 2191-2199.	2.3	92
218	Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis. Gastroenterology, 2016, 151, 97-109.e4.	0.9	147
219	Tu1993 Sexual Dysfunction in Women With Inflammatory Bowel Disease: A New IBD-Specific Scale. Gastroenterology, 2016, 150, S1000.	0.9	10
220	Clinical Activity and Quality of Life Indices Are Valid Across Ulcerative Colitis But Not Crohn's Disease Phenotypes. Digestive Diseases and Sciences, 2016, 61, 2627-2635.	1.5	19
221	P-014 Circulating C-Reactive Protein and Interleukin-6 and Risk of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2016, 22, S13-S14.	2.3	0
222	Racial Disparities in Inhospital Outcomes for Hepatocellular Carcinoma in the United States. Mayo Clinic Proceedings, 2016, 91, 1173-1182.	1.9	18
223	Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn's Disease. American Journal of Gastroenterology, 2016, 111, 1816-1822.	0.7	92
224	A Pleiotropic Missense Variant in SLC39A8 Is Associated With Crohn's Disease and Human Gut Microbiome Composition. Gastroenterology, 2016, 151, 724-732.	0.9	146
225	Stool DNA Analysis is Cost-Effective for Colorectal Cancer Surveillance in Patients With Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2016, 14, 1778-1787.e8.	5.0	14
226	A protein-truncating R179X variant in RNF186 confers protection against ulcerative colitis. Nature Communications, 2016, 7, .	10.8	57
227	State of Adult Trainee Inflammatory Bowel Disease Education in the United States. Inflammatory Bowel Diseases, 2016, 22, 1609-1615.	2.3	29
228	Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis. Inflammatory Bowel Diseases, 2016, 22, 880-885.	2.3	52
229	Toward reducing bias in clinical trials: central readers for endoscopic endpoints. Gastrointestinal Endoscopy, 2016, 83, 198-200.	1.0	4
230	Chromoendoscopy Is Better: So Why Am I Not (yet) Using it for Routine Inflammatory Bowel Disease Surveillance?. Clinical Gastroenterology and Hepatology, 2016, 14, 720-722.	5.0	11
231	Association Between Circulating Levels of C-Reactive Protein and Interleukin-6 and Risk of Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2016, 14, 818-824.e6.	5.0	81
232	Statin Use Is Associated With Reduced Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2016, 14, 973-979.	5.0	77
233	Systematic Review and Meta-analysis: Phenotype and Clinical Outcomes of Older-onset Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2016, 10, 1224-1236.	0.9	158
234	Computer-assisted expert case definition in electronic health records. International Journal of Medical Informatics, 2016, 86, 62-70.	2.6	34

#	Article	IF	Citations
235	Diagnostic and Therapeutic Yield of Endoscopy in Patients with Elevated INR and Gastrointestinal Bleeding. American Journal of Medicine, 2016, 129, 628-634.	1.4	13
236	Risk of New or Recurrent Cancer in Patients With Inflammatory Bowel Disease and Previous Cancer Exposed to Immunosuppressive and Anti-Tumor Necrosis Factor Agents. Clinical Gastroenterology and Hepatology, 2016, 14, 58-64.	5.0	112
237	Vedolizumab Therapy Is Associated with an Improvement in Sleep Quality and Mood in Inflammatory Bowel Diseases. Digestive Diseases and Sciences, 2016, 62, 197-206.	1.5	65
238	Influence of Age and Gender on Assessment of IBD Quality Measures in Patients with Ulcerative Colitis. American Journal of Gastroenterology, 2016, 111, S289.	0.7	0
239	High School Diet and Risk of Crohn's Disease and Ulcerative Colitis. Inflammatory Bowel Diseases, 2015, , 1.	2.3	92
240	Development of phenotype algorithms using electronic medical records and incorporating natural language processing. BMJ, The, 2015, 350, h1885-h1885.	0.2	269
241	Body Mass Index, Genetic Susceptibility, and Risk of Complications Among Individuals with Crohn's Disease. Inflammatory Bowel Diseases, 2015, , 1.	2.3	58
242	Common Genetic Variants Influence Circulating Vitamin D Levels in Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2015, 21, 2507-2514.	2.3	33
243	Endogenous Levels of Circulating Androgens and Risk of Crohn's Disease and Ulcerative Colitis Among Women. Inflammatory Bowel Diseases, 2015, , 1.	2.3	19
244	Zinc intake and risk of Crohn's disease and ulcerative colitis: a prospective cohort study. International Journal of Epidemiology, 2015, 44, 1995-2005.	2.8	109
245	Reply. Clinical Gastroenterology and Hepatology, 2015, 13, 1703-1704.	5.0	0
246	Colonoscopy Is Associated With a Reduced Risk for Colon Cancer and Mortality in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2015, 13, 322-329.e1.	5.0	120
247	Epidemiology and risk factors for IBD. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 205-217.	33.1	1,625
248	High C-Reactive Protein Is Associated with Poor Sleep Quality Independent of Nocturnal Symptoms in Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2015, 60, 2136-2143.	1.5	57
249	Rectosigmoid Localization of Radiopaque Markers Does Not Correlate with Prolonged Balloon Expulsion in Chronic Constipation: Results from a Multicenter Cohort. American Journal of Gastroenterology, 2015, 110, 1049-1055.	0.7	33
250	Reply. Clinical Gastroenterology and Hepatology, 2015, 13, 814.	5.0	0
251	Variation in Treatment of Patients With Inflammatory Bowel Diseases at Major Referral Centers in the United States. Clinical Gastroenterology and Hepatology, 2015, 13, 1197-1200.	5.0	53
252	Measures of Obesity and Risk of Crohn's Disease and Ulcerative Colitis. Inflammatory Bowel Diseases, 2015, 21, 361-368.	2.3	163

#	Article	IF	Citations
253	Methods to Develop an Electronic Medical Record Phenotype Algorithm to Compare the Risk of Coronary Artery Disease across 3 Chronic Disease Cohorts. PLoS ONE, 2015, 10, e0136651.	1.5	93
254	The Cost-Effectiveness of Competing Strategies for Managing Multiply Recurrent Clostridium difficile Infection: Examining the Impact of Universal Stool Banks and Encapsulated Fecal Microbiota Transplantation. American Journal of Gastroenterology, 2015, 110, S933-S934.	0.7	1
255	Correlations Between Clinical Activity Indices or Quality of Life Scores to Endoscopic Activity Scores Do not Vary According to Age at Diagnosis, Disease Location, and Disease Behavior in Inflammatory Bowel Disease. American Journal of Gastroenterology, 2015, 110, S799-S800.	0.7	0
256	Restricted Eating Patterns in Chronic Constipation Are Associated With Bloating and Abdominal Symptoms More so Than Rectal and Stool Symptoms. American Journal of Gastroenterology, 2015, 110, S761.	0.7	0
257	Comorbid Depression, Not Symptom Severity or Disease-Specific Quality of Life, Predicts Work Absenteeism in Chronic Constipation. American Journal of Gastroenterology, 2015, 110, S754.	0.7	0
258	Elevated C-Reactive Protein is Associated With Poor Sleep Quality in Patients With Inflammatory Bowel Disease. American Journal of Gastroenterology, 2014, 109, S488-S489.	0.7	0
259	Early life environment and natural history of inflammatory bowel diseases. BMC Gastroenterology, 2014, 14, .	1.7	35
260	Pretreatment 25-Hydroxyvitamin D Levels and Durability of Anti–Tumor Necrosis Factor–α Therapy in Inflammatory Bowel Diseases. Journal of Parenteral and Enteral Nutrition, 2014, 38, 385-391.	2.1	108
261	Evaluation of matched control algorithms in EHR-based phenotyping studies: A case study of inflammatory bowel disease comorbidities. Journal of Biomedical Informatics, 2014, 52, 105-111.	3.0	29
262	Vitamin D deficiency is associated with community-acquired clostridium difficile infection: a case–control study. BMC Infectious Diseases, 2014, 14, .	1.7	19
263	Impact of Mode of Delivery on Outcomes in Patients with Perianal Crohn's Disease. Inflammatory Bowel Diseases, 2014, 20, 1391-1398.	2.3	44
264	Venous Thromboembolism in Patients with Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2014, 20, 631-636.	2.3	62
265	Natural History of Crohn's Disease Following Total Colectomy and End Ileostomy. Inflammatory Bowel Diseases, 2014, 20, 1236-1241.	2.3	38
266	Genetic Polymorphisms in Metabolizing Enzymes Modifying the Association Between Smoking and Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2014, 20, 783-789.	2.3	40
267	Thromboprophylaxis Is Associated With Reduced Post-hospitalization Venous Thromboembolic Events in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2014, 12, 1905-1910.	5.0	72
268	Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease. Journal of Crohn's and Colitis, 2014, 8, 956-963.	0.9	54
269	Cost-effectiveness of Competing Strategies for Management of Recurrent Clostridium difficile Infection: A Decision Analysis. Clinical Infectious Diseases, 2014, 58, 1507-1514.	3.7	141
270	Association Between Reduced Plasma 25-Hydroxy Vitamin D and Increased Risk of Cancer in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2014, 12, 821-827.	5.0	110

#	Article	IF	Citations
271	Differential Effect of Genetic Burden on Disease Phenotypes in Crohn's Disease and Ulcerative Colitis: Analysis of a North American Cohort. American Journal of Gastroenterology, 2014, 109, 395-400.	0.7	83
272	Long-term intake of dietary fat and risk of ulcerative colitis and Crohn's disease. Gut, 2014, 63, 776-784.	10.3	482
273	Case 25-2014. New England Journal of Medicine, 2014, 371, 668-675.	26.4	74
274	Sleep Duration Affects Risk for Ulcerative Colitis: A Prospective Cohort Study. Clinical Gastroenterology and Hepatology, 2014, 12, 1879-1886.	5.0	111
275	Serum Inflammatory Markers and Risk of Colorectal Cancer in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2014, 12, 1342-1348.e1.	5.0	44
276	Reply. Clinical Gastroenterology and Hepatology, 2014, 12, 1577-1578.	5.0	0
277	Reply. Gastroenterology, 2014, 146, 1134-1135.	0.9	0
278	SMAD3 gene variant is a risk factor for recurrent surgery in patients with Crohn's disease. Journal of Crohn's and Colitis, 2014, 8, 845-851.	0.9	52
279	Cost-effectiveness analysis of chromoendoscopy for colorectal cancer surveillance in patients with ulcerative colitis. Gastrointestinal Endoscopy, 2014, 79, 455-465.	1.0	73
280	Mode of Childbirth and Long-Term Outcomes in Women with Inflammatory Bowel Diseases. Digestive Diseases and Sciences, 2014, 60, 471-477.	1.5	28
281	Environmental Risk Factors for Inflammatory Bowel Diseases: A Review. Digestive Diseases and Sciences, 2014, 60, 290-298.	1.5	173
282	The exposome in inflammatory bowel disease. Tropical Gastroenterology: Official Journal of the Digestive Diseases Foundation, 2014, 35, 135-140.	0.2	14
283	Early Life Environment and Natural History of Inflammatory Bowel Diseases. American Journal of Gastroenterology, 2014, 109, S486.	0.7	0
284	Mode of Childbirth and Long-term Outcomes in Women With Inflammatory Bowel Diseases: ACG Governors Award for Excellence in Clinical Research. American Journal of Gastroenterology, 2014, 109, S474.	0.7	0
285	Low Serum Vitamin D is Associated With Increased Risk of Community-Acquired Clostridium difficile Infection. American Journal of Gastroenterology, 2014, 109, S191-S192.	0.7	0
286	Can Mucosal Healing Be a Cost-effective Endpoint for Biologic Therapy in Crohn's Disease? A Decision Analysis. Inflammatory Bowel Diseases, 2013, 19, 37-44.	2.3	45
287	Older Age Is Associated with Higher Rate of Discontinuation of Anti-TNF Therapy in Patients with Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2013, 19, 309-315.	2.3	151
288	Treatment of Intra-Abdominal Abscesses in Crohn's Disease: A Nationwide Analysis of Patterns and Outcomes of Care. Digestive Diseases and Sciences, 2013, 58, 2013-2018.	1.5	27

#	Article	IF	Citations
289	Oral contraceptives, reproductive factors and risk of inflammatory bowel disease. Gut, 2013, 62, 1153-1159.	10.3	201
290	Interobserver Agreement for the Detection of Barrett's Esophagus with Optical Frequency Domain Imaging. Digestive Diseases and Sciences, 2013, 58, 2261-2265.	1.5	48
291	Dyssynergic Defecation: A Treatable Cause of Persistent Symptoms When Inflammatory Bowel Disease Is in Remission. Digestive Diseases and Sciences, 2013, 58, 3600-3605.	1.5	41
292	A Prospective Study of Long-term Intake of Dietary Fiber and Risk of Crohn's Disease and Ulcerative Colitis. Gastroenterology, 2013, 145, 970-977.	0.9	606
293	Personalizing therapy for inflammatory bowel diseases. Expert Review of Gastroenterology and Hepatology, 2013, 7, 549-558.	1.6	11
294	Sleep Disturbance and Risk of Active Disease in Patients With Crohn's Disease and Ulcerative Colitis. Clinical Gastroenterology and Hepatology, 2013, 11, 965-971.	5.0	244
295	Association Between Depressive Symptoms and Incidence of Crohn's Disease and Ulcerative Colitis: Results From the Nurses' Health Study. Clinical Gastroenterology and Hepatology, 2013, 11, 57-62.	5.0	147
296	Antibiotic exposure is associated with development of inflammatory bowel disease. Journal of Pediatrics, 2013, 162, 1077.	1.6	1
297	Impact of Coexistent Celiac Disease on Phenotype and Natural History of Inflammatory Bowel Diseases. American Journal of Gastroenterology, 2013, 108, 1123-1129.	0.7	53
298	Guidelines for Diagnosis, Treatment, and Prevention of Clostridium difficile Infections. American Journal of Gastroenterology, 2013, 108, 478-498.	0.7	1,535
299	Similar Risk of Depression and Anxiety Following Surgery or Hospitalization for Crohn's Disease and Ulcerative Colitis. American Journal of Gastroenterology, 2013, 108, 594-601.	0.7	83
300	Infection-related hospitalizations are associated with increased mortality in patients with inflammatory bowel diseases. Journal of Crohn's and Colitis, 2013, 7, 107-112.	0.9	176
301	Improving Case Definition of Crohn's Disease and Ulcerative Colitis in Electronic Medical Records Using Natural Language Processing. Inflammatory Bowel Diseases, 2013, 19, 1411-1420.	2.3	163
302	Physical activity and risk of inflammatory bowel disease: prospective study from the Nurses' Health Study cohorts. BMJ, The, 2013, 347, f6633-f6633.	0.2	136
303	Normalization of Plasma 25-Hydroxy Vitamin D Is Associated with Reduced Risk of Surgery in Crohn's Disease. Inflammatory Bowel Diseases, 2013, , 1.	2.3	179
304	P-043 The Risk of Ectopic Pregnancy in Patients with Inflammatory Bowel Disease—A Retrospective Case Control Study. Inflammatory Bowel Diseases, 2013, 19, S42.	2.3	0
305	Early Life Factors and Risk of Inflammatory Bowel Disease in Adulthood. Inflammatory Bowel Diseases, 2013, 19, 542-547.	2.3	55
306	P-056 Aryl Hydrocarbon Receptor Expression—A Comparison Between Patients with IBD and Healthy Controls, and Association with Serum Fatty Acids. Inflammatory Bowel Diseases, 2013, 19, S49-S50.	2.3	0

#	Article	IF	Citations
307	How Does Genotype Influence Disease Phenotype in Inflammatory Bowel Disease?. Inflammatory Bowel Diseases, 2013, , 1.	2.3	14
308	Does Parental Age Influence the Risk of Inflammatory Bowel Disease in Offspring?. American Journal of Gastroenterology, 2013, 108, S547.	0.7	1
309	Cost-effectiveness of Competing Strategies for Recurrent Clostridium difficile Infection: ACG/AstraZeneca Fellow Award. American Journal of Gastroenterology, 2013, 108, S473.	0.7	2
310	Natural History of Crohn's Disease Following Permanent Ileostomy: Implications for Endoscopic Surveillance. American Journal of Gastroenterology, 2013, 108, S510.	0.7	0
311	Preventability of Venous Thromboembolism in Patients with Inflammatory Bowel Disease. American Journal of Gastroenterology, 2013, 108, S511-S512.	0.7	0
312	Aspirin, Nonsteroidal Anti-inflammatory Drug Use, and Risk for Crohn Disease and Ulcerative Colitis. Annals of Internal Medicine, 2012, 156, 350-359.	7.3	247
313	Impact of pregnancy on health-related quality of life of patients with inflammatory bowel disease. Journal of Digestive Diseases, 2012, 13, 472-477.	1.0	10
314	Geographical variation and incidence of inflammatory bowel disease among US women. Gut, 2012, 61, 1686-1692.	10.3	199
315	Aspirin Protects Against Barrett's Esophagus in a Multivariate Logistic Regression Analysis. Clinical Gastroenterology and Hepatology, 2012, 10, 722-727.	5.0	59
316	Effects of Cancer Treatment on Inflammatory Bowel Disease Remission and Reactivation. Clinical Gastroenterology and Hepatology, 2012, 10, 1021-1027.e1.	5.0	56
317	Detecting and Treating Clostridium Difficile Infections in Patients with Inflammatory Bowel Disease. Gastroenterology Clinics of North America, 2012, 41, 339-353.	1.6	34
318	Cyclic Vomiting Syndrome (CVS): is there a difference based on onset of symptoms - pediatric versus adult?. BMC Gastroenterology, 2012, 12, .	1.7	91
319	Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature, 2012, 491, 119-124.	30.7	4,662
320	Higher Predicted Vitamin D Status Is Associated With Reduced Risk of Crohn's Disease. Gastroenterology, 2012, 142, 482-489.	0.9	412
321	Hormone Therapy Increases Risk of Ulcerative Colitis but not Crohn's Disease. Gastroenterology, 2012, 143, 1199-1206.	0.9	129
322	Reply to Dr. McNabb-Baltar's letter. Journal of Crohn's and Colitis, 2012, 6, 868.	0.9	0
323	863 Higher Dietary Fiber Intake is Associated With Lower Risk of Crohn's Disease but Not Ulcerative Colitis - a Prospective Study. Gastroenterology, 2012, 142, S-148.	0.9	4
324	Vitamin D and IBD: More Pieces to the Puzzle, Still No Complete Picture. Inflammatory Bowel Diseases, 2012, 18, 1391-1393.	2.3	5

#	Article	IF	Citations
325	Environmental Triggers for Inflammatory Bowel Disease. Current Gastroenterology Reports, 2012, 15, .	2.2	100
326	Strategies for the Prevention of Postoperative Recurrence in Crohn's Disease: Results of a Decision Analysis. American Journal of Gastroenterology, 2011, 106, 2009-2017.	0.7	46
327	Missed polyps, missed opportunities. Gastrointestinal Endoscopy, 2011, 74, 262-265.	1.0	2
328	A Prospective Study of Vitamin D Status and Risk of Incident Crohn's Disease and Ulcerative Colitis. Gastroenterology, 2011, 140, S-113.	0.9	1
329	Geographic variation and the incidence of inflammatory bowel disease among U.S. women. Inflammatory Bowel Diseases, 2011, 17, S15.	2.3	0
330	Deep Vein Thrombosis and Pulmonary Embolism in Hospitalized Patients with Cirrhosis: A Nationwide Analysis. Digestive Diseases and Sciences, 2011, 56, 2152-2159.	1.5	74
331	QuantiFERON TB gold testing for tuberculosis screening in an inflammatory bowel disease cohort in the United States. Inflammatory Bowel Diseases, 2011, 17, 77-83.	2.3	67
332	Physician density and hospitalization for inflammatory bowel disease. Inflammatory Bowel Diseases, 2011, 17, 633-638.	2.3	10
333	Ambient air pollution correlates with hospitalizations for inflammatory bowel disease. Inflammatory Bowel Diseases, 2011, 17, 1138-1145.	2.3	163
334	Temporal trends in disease outcomes related to Clostridium difficile infection in patients with inflammatory bowel disease. Inflammatory Bowel Diseases, 2011, 17, 976-983.	2.3	143
335	Certolizumab Pegol Compared to Natalizumab in Patients with Moderate to Severe Crohn's Disease: Results of a Decision Analysis. Digestive Diseases and Sciences, 2011, 57, 472-480.	1.5	18
336	Geographic Variations and Risk of Crohn's Disease and Ulcerative Colitis: Results from Two Large Prospective Cohorts: ACG IBD Award. American Journal of Gastroenterology, 2011, 106, S489.	0.7	0
337	A Prospective Study of Aspirin, Non-steroidal Anti-inflammatory Drug Use and Risk of Crohn's Disease and Ulcerative Colitis: ACG Governors Award for Excellence in Clinical Research. American Journal of Gastroenterology, 2011, 106, S462.	0.7	0
338	Impact of Autonomic Dysfunction on Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 2010, 44, 272-279.	1.6	29
339	Higher Physician Density is Associated with Lower Incidence of Late-stage Colorectal Cancer. Journal of General Internal Medicine, 2010, 25, 1164-1171.	1.5	71
340	A Noninvasive Clinical Scoring Model Predicts Risk of Nonalcoholic Steatohepatitis in Morbidly Obese Patients. Obesity Surgery, 2010, 20, 685-691.	1.5	57
341	Does primary sclerosing cholangitis impact quality of life in patients with inflammatory bowel disease?. Inflammatory Bowel Diseases, 2010, 16, 494-500.	2.3	30
342	Clostridium difficile and inflammatory bowel disease. Inflammatory Bowel Diseases, 2010, 16, 1445-1446.	2.3	5

#	Article	IF	Citations
343	Simple score to identify colectomy risk in ulcerative colitis hospitalizations. Inflammatory Bowel Diseases, 2010, 16, 1532-1540.	2.3	37
344	Trends in Ambulatory and Emergency Room Visits for Inflammatory Bowel Diseases in the United States: 1994–2005. American Journal of Gastroenterology, 2010, 105, 363-370.	0.7	50
345	A Novel Risk Score to Stratify Severity of Crohn's Disease Hospitalizations. American Journal of Gastroenterology, 2010, 105, 1799-1807.	0.7	60
346	Length of Office Visits for Gastrointestinal Disease: Impact of Physician Specialty. American Journal of Gastroenterology, 2010, 105, 1719-1725.	0.7	8
347	Improved Efficacy of Biological Maintenance Therapy in “Early” Compared With “Late” Crohn's Disease: Strike While the Iron Is Hot With Anti-TNF Agents?. American Journal of Gastroenterology, 2010, 105, 1583-1585.	0.7	9
348	Clostridium difficile Is Associated With Poor Outcomes in Patients With Cirrhosis: A National and Tertiary Center Perspective. American Journal of Gastroenterology, 2010, 105, 106-113.	0.7	159
349	Clostridium Difficile and Inflammatory Bowel Disease. Medical Clinics of North America, 2010, 94, 135-153.	2.2	42
350	Imatinib and Panax Ginseng : A Potential Interaction Resulting in Liver Toxicity. Annals of Pharmacotherapy, 2010, 44, 926-928.	1.5	117
351	Impact ofClostridium difficileon inflammatory bowel disease. Expert Review of Gastroenterology and Hepatology, 2010, 4, 589-600.	1.6	31
352	Clostridium difficile infection: epidemiology, risk factors and management. Nature Reviews Gastroenterology and Hepatology, 2010, 8, 17-26.	33.1	336
353	Fracture-Associated Hospitalizations in Patients with Inflammatory Bowel Disease. Digestive Diseases and Sciences, 2010, 56, 176-182.	1.5	20
354	A Nationwide Analysis of Changes in Severity and Outcomes of Inflammatory Bowel Disease Hospitalizations. Journal of Gastrointestinal Surgery, 2010, 15, 267-276.	1.2	62
355	Influence of Body Mass Index on Quality of Life and Disease Activity in Crohn's Patients: 2010 ACG/Centocor IBD Abstract Award. American Journal of Gastroenterology, 2010, 105, S477.	0.7	0
356	Inflammatory bowel disease in the elderly is associated with worse outcomes: A national study of hospitalizations. Inflammatory Bowel Diseases, 2009, 15, 182-189.	2.3	187
357	History of medical hospitalization predicts future need for colectomy in patients with ulcerative colitis. Inflammatory Bowel Diseases, 2009, 15, 176-181.	2.3	72
358	Durability of infliximab in Crohn's disease. Inflammatory Bowel Diseases, 2009, 15, 1837-1843.	2.3	16
359	Higher hospital volume predicts endoscopy but not the in-hospital mortality rate in patients with acute variceal hemorrhage. Gastrointestinal Endoscopy, 2009, 69, 221-229.	1.0	10
360	Higher hospital volume is associated with lower mortality in acute nonvariceal upper-GI hemorrhage. Gastrointestinal Endoscopy, 2009, 70, 422-432.	1.0	26

#	Article	IF	Citations
361	S1145 Long-Term Impact of Clostridium difficile On Inflammatory Bowel Disease. Gastroenterology, 2009, 136, A-199.	0.9	8
362	Outcomes of Weekend Admissions for Upper Gastrointestinal Hemorrhage: A Nationwide Analysis. Clinical Gastroenterology and Hepatology, 2009, 7, 296-302.e1.	5.0	164
363	Reply. Clinical Gastroenterology and Hepatology, 2009, 7, 912.	5.0	1
364	Clostridium Difficile and Inflammatory Bowel Disease. Gastroenterology Clinics of North America, 2009, 38, 711-728.	1.6	61
365	Laparoscopic Resection for Inflammatory Bowel Disease: Outcomes from a Nationwide Sample. Journal of Gastrointestinal Surgery, 2009, 14, 58-65.	1.2	21
366	Pre-operative Small Bowel Follow Through Detects more Crohn's Disease Strictures than CT Enterography in Patients with Multiple Strictures: Comparison with Intra-operative Findings. American Journal of Gastroenterology, 2009, 104, S447.	0.7	0
367	Effect of Hospital Volume and Teaching Status on Outcomes of Acute Liver Failure. Liver Transplantation, 2008, 14, 1347-1356.	1.6	28
368	Clostridium difficile and inflammatory bowel disease. Inflammatory Bowel Diseases, 2008, 14, 1432-1442.	2.3	209
369	Does It Matter Where You Are Hospitalized for Inflammatory Bowel Disease? A Nationwide Analysis of Hospital Volume. American Journal of Gastroenterology, 2008, 103, 2789-2798.	0.7	121
370	Deleterious Effect of Cirrhosis on Outcomes After Motor Vehicle Crashes Using the Nationwide Inpatient Sample. American Journal of Gastroenterology, 2008, , ???-???.	0.7	34
371	Permanent Work Disability in Crohn's Disease. American Journal of Gastroenterology, 2008, 103, 154-161.	0.7	92
372	Racial Differences in Liver Transplantation Outcomes in the MELD Era. American Journal of Gastroenterology, 2008, 103, 901-910.	0.7	79
373	Impact of Anti-TNF-α Treatment Failure Complicating Long-Term Maintenance Therapy for Crohn's Disease. American Journal of Gastroenterology, 2008, 103, S447.	0.7	0
374	Perception and Reality. American Journal of Gastroenterology, 2008, 103, S443.	0.7	0
375	Vitamin D Deficiency in Inflammatory Bowel Disease Patients. American Journal of Gastroenterology, 2008, 103, S442-S443.	0.7	0
376	Use of a Blood IFN-γ Release Assay (Quantiferon-Tb Gold Test) for Tuberculosis Screening in Inflammatory Bowel Disease (IBD). American Journal of Gastroenterology, 2008, 103, S438-S439.	0.7	0
377	Severe Pulmonary Toxicity After Azathioprine/6-Mercaptopurine Initiation for the Treatment of Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 2007, 41, 682-688.	1.6	55
378	Disparities in Colon Cancer Screening in the Medicare Population. Archives of Internal Medicine, 2007, 167, 258.	8.1	123

#	Article	IF	Citations
379	Caroli's disease: Identification and treatment strategy. Current Gastroenterology Reports, 2007, 9, 151-155.	2.2	57
380	Epidemiology of Primary and Secondary Liver Cancers. Seminars in Interventional Radiology, 2006, 23, 047-063.	0.6	186
381	The Crohn's disease polymorphism, ATG16L1 T300A, alters the gut microbiota and enhances the local Th1/Th17 response. ELife, 0, 8, .	1.0	134
382	Dietary Nut and Legume Intake and Risk of Crohn's Disease and Ulcerative Colitis. Inflammatory Bowel Diseases, 0, 31, 2458-2466.	2.3	3
383	Delayed Remission With Advanced Therapies Is Not Associated With Worse 1-Year Outcomes in Inflammatory Bowel Disease. American Journal of Gastroenterology, 0, 121, 1944-1953.	0.7	0
384	Overall and Comparative Risk of Shingles With Advanced Therapies in Patients With Inflammatory Bowel Diseases. Alimentary Pharmacology and Therapeutics, 0, 63, 686-695.	2.7	3
385	Cross-Sectional Imaging Features Associated With Disease Progression in Crohn's Disease. Inflammatory Bowel Diseases, 0, 32, 228-236.	2.3	2
386	Vedolizumab Versus Other Biologics and the Risk of Venous Thromboembolism in Patients with Pediatric-Onset Inflammatory Bowel Diseases: A Target Trial Emulation Study. Paediatric Drugs, 0, 27, 761-770.	2.4	2
387	AGA Living Clinical Practice Guideline on the Pharmacologic Management of Moderate-to-Severe Crohn's Disease. Gastroenterology, 0, 169, 1397-1448.	0.9	27
388	Women and Younger Adults With Inflammatory Bowel Disease are at Greater Risk of Financial Toxicity From Inflammatory Bowel Disease. American Journal of Gastroenterology, 0, 121, 2271-2279.	0.7	0
389	Phenotypic Differences in Inflammatory Bowel Diseases Across Race, Ethnicity, and Geography: A Systematic Review of 237 Population-Based Studies. Clinical Gastroenterology and Hepatology, 0, 24, 1790-1799.	5.0	0
390	Dairy Intake and Risk of Incident Inflammatory Bowel Disease in US Men and Women. Clinical and Translational Gastroenterology, 0, 17, e00988.	1.7	0
391	Frailty in inflammatory bowel disease: a missing link in personalized care for the aging IBD population. Inflammatory Bowel Diseases, 0, 32, 1612-1626.	2.3	0
392	Differences in Outcomes After Ileocecal Resection in Older Adults With Crohn's Disease in the Biologic Era. American Journal of Gastroenterology, 0, 121, 2055-2058.	0.7	0
393	Disease reprogression following surgical resection in Crohn disease. Inflammatory Bowel Diseases, 0, 32, 1304-1312.	2.3	0
394	Advanced therapies for extraintestinal manifestations of IBD: a systematic review and meta-analysis. Inflammatory Bowel Diseases, 0, , .	2.3	0
395	Tu1557 COMPARATIVE SAFETY OF LONG-TERM BUDESONIDE VERSUS SYSTEMIC STEROIDS IN OLDER ADULTS WITH INFLAMMATORY BOWEL DISEASES OR MICROSCOPIC COLITIS. Gastrointestinal Endoscopy, 0, 103, S-1300.	1.0	0
396	Tu1588 COMPARATIVE RISK OF CANCER WITH IL-12/23 OR IL-23 INHIBITORS AND ANTI-TNFS IN INFLAMMATORY BOWEL DISEASES. Gastrointestinal Endoscopy, 0, 103, S-1316.	1.0	0

#	Article	IF	Citations
397	323 IMPACT OF BASELINE PHYSICAL ACTIVITY ON RISK OF DISEASE FLARES, QUALITY OF LIFE, AND GUT MICROBIOME IN INFLAMMATORY BOWEL DISEASES: A PROSPECTIVE COHORT STUDY. Gastrointestinal Endoscopy, 0, 103, S-877-S-878.	1.0	0
398	1175 MULTI-BACTERIA BIOMARKER PANEL FOR INFLAMMATORY BOWEL DISEASE DIAGNOSIS - AN INTERNATIONAL MULTI-CENTER STUDY. Gastrointestinal Endoscopy, 0, 103, S-923.	1.0	0
399	Tu1495 MACHINE-LEARNING BASED STRATIFICATION IDENTIFIES TREATMENT TRAJECTORY SUBTYPES AND UNMET NEED IN INFLAMMATORY BOWEL DISEASES. Gastrointestinal Endoscopy, 0, 103, S-1269-S-1270.	1.0	0
400	Mo1554 COMPARATIVE EFFECTIVENESS OF ADVANCED THERAPIES FOR PREVENTING PENETRATING COMPLICATIONS IN CROHN'S DISEASE: AN ADMINISTRATIVE CLAIMS-BASED STUDY. Gastrointestinal Endoscopy, 0, 103, S-1185.	1.0	0
401	Sa1569 INCIDENCE AND PREVALENCE OF COMMON GYNECOLOGIC CONDITIONS IN WOMEN WITH INFLAMMATORY BOWEL DISEASE: ENDOMETRIOSIS AND FIBROIDS. Gastrointestinal Endoscopy, 0, 103, S-988.	1.0	0
402	703 THE IMPACT OF NORMALIZATION OF HISTOLOGY ON DISEASE COURSE IN MICROSCOPIC COLITIS: A RETROSPECTIVE COHORT STUDY. Gastrointestinal Endoscopy, 0, 103, S-165.	1.0	0
403	Sa1500 MIRIKIZUMAB TREATMENT DECREASES ULCERATIVE COLITIS-RELATED SURGERY AND HOSPITALIZATION RATES: 4-YEAR LUCENT STUDIES RESULTS. Gastrointestinal Endoscopy, 0, 103, S-956-S-957.	1.0	0
404	Sa1599 IMPROVEMENTS IN WORK PRODUCTIVITY OVER TIME IN PATIENTS WITH IBD-ASSOCIATED PERIPHERAL SPONDYLOARTHRITIS. Gastrointestinal Endoscopy, 0, 103, S-1001.	1.0	0
405	36 IMPACT OF PRIOR EXPOSURE TO ADVANCED THERAPY AND TIMING OF DISCONTINUATION ON RISK OF SERIOUS INFECTIONS IN PATIENTS WITH IBD STARTING A NEW ADVANCED THERAPY. Gastrointestinal Endoscopy, 0, 103, S-858.	1.0	0
406	Tu1494 MACHINE LEARNING-BASED STRATIFICATION TO DEFINE DISTINCT DISEASE TRAJECTORIES FOLLOWING ADVANCED THERAPY INITIATION IN CROHN'S DISEASE AND ULCERATIVE COLITIS. Gastrointestinal Endoscopy, 0, 103, S-1269.	1.0	0
407	Tu1592 CANCER RISK ASSOCIATED WITH COMBINATION METHOTREXATE AND ANTI-TNF THERAPY VERSUS ANTI-TNF MONOTHERAPY FOR INFLAMMATORY BOWEL DISEASE: A RETROSPECTIVE COHORT STUDY.. Gastrointestinal Endoscopy, 0, 103, S-1318.	1.0	0
408	538 COMPARATIVE EFFECTIVENESS OF JAK INHIBITORS VERSUS IL-23 INHIBITORS IN USTEKINUMAB FAILURES IN MODERATE-TO-SEVERE CROHN'S DISEASE. Gastrointestinal Endoscopy, 0, 103, S-889.	1.0	0
409	Tu1584 CANCER RISK WITH ADVANCED THERAPIES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES: AN ADMINISTRATIVE CLAIMSBASED STUDY. Gastrointestinal Endoscopy, 0, 103, S-1314.	1.0	0
410	Sa1627 IMPACT OF ADVANCED THERAPY INITIATION ON ANTIBIOTIC DEPENDENCE IN CHRONIC POUCHITIS. Gastrointestinal Endoscopy, 0, 103, S-1016-S-1017.	1.0	0
411	Microbiome-Directed Therapy for Fatigue in Quiescent Inflammatory Bowel Disease: A Randomized Placebo-Controlled Trial of Multistrain Probiotic Supplementation. American Journal of Gastroenterology, 0, , .	0.7	0
412	Impact of advanced therapy initiation on antibiotic dependence in chronic pouchitis. Inflammatory Bowel Diseases, 0, , .	2.3	0
413	The impact of normalization of histology on disease course in microscopic colitis: a retrospective cohort study. Inflammatory Bowel Diseases, 0, , .	2.3	0
414	Cancer risk with methotrexate-TNF antagonist combination therapy compared to TNF-antagonist monotherapy in IBD. Inflammatory Bowel Diseases, 0, , .	2.3	0

#	Article	IF	Citations
415	Polygenic Risk Scores Show Distinct Genetic Architectures of IBD-Associated Comorbidities. Digestive Diseases and Sciences, 0, , .	1.5	0